NO20052976L - Fosfodiesterase-4-inhibitorer. - Google Patents

Fosfodiesterase-4-inhibitorer.

Info

Publication number
NO20052976L
NO20052976L NO20052976A NO20052976A NO20052976L NO 20052976 L NO20052976 L NO 20052976L NO 20052976 A NO20052976 A NO 20052976A NO 20052976 A NO20052976 A NO 20052976A NO 20052976 L NO20052976 L NO 20052976L
Authority
NO
Norway
Prior art keywords
phosphodiesterase
inhibitors
compounds
formulas
iii
Prior art date
Application number
NO20052976A
Other languages
English (en)
Norwegian (no)
Other versions
NO20052976D0 (no
Inventor
Richard A Schumacher
Ashok Tehim
Allen T Hopper
Elizabeth Doorly Graham
Original Assignee
Memory Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memory Pharm Corp filed Critical Memory Pharm Corp
Publication of NO20052976D0 publication Critical patent/NO20052976D0/no
Publication of NO20052976L publication Critical patent/NO20052976L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20052976A 2002-11-19 2005-06-17 Fosfodiesterase-4-inhibitorer. NO20052976L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42722102P 2002-11-19 2002-11-19
PCT/US2003/036986 WO2004046113A2 (fr) 2002-11-19 2003-11-19 Inhibiteurs de la phosphodiesterase 4

Publications (2)

Publication Number Publication Date
NO20052976D0 NO20052976D0 (no) 2005-06-17
NO20052976L true NO20052976L (no) 2005-08-18

Family

ID=32326501

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052976A NO20052976L (no) 2002-11-19 2005-06-17 Fosfodiesterase-4-inhibitorer.

Country Status (16)

Country Link
US (3) US7087625B2 (fr)
EP (1) EP1569908B1 (fr)
JP (1) JP2006508987A (fr)
KR (1) KR20050075430A (fr)
CN (1) CN100513397C (fr)
AT (1) ATE481387T1 (fr)
AU (1) AU2003295656B2 (fr)
BR (1) BR0315705A (fr)
CA (1) CA2506297A1 (fr)
DE (1) DE60334243D1 (fr)
MX (1) MXPA05005345A (fr)
NO (1) NO20052976L (fr)
NZ (1) NZ540138A (fr)
RU (1) RU2356893C2 (fr)
WO (1) WO2004046113A2 (fr)
ZA (1) ZA200503995B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7153871B2 (en) * 2001-01-22 2006-12-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
US20030149052A1 (en) * 2002-01-22 2003-08-07 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
EP1539697A1 (fr) * 2002-07-19 2005-06-15 Memory Pharmaceutical Corporation Inhibiteurs de phosphodiesterase 4 comprenant des analogues de diphenylamine et d'aniline n-substitues
JP2006502995A (ja) * 2002-07-19 2006-01-26 メモリー・ファーマシューティカルズ・コーポレイション ホスホジエステラーゼ４阻害剤としての６−アミノ−１ｈ−インダゾール及び４−アミノベンゾフラン化合物
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
KR20120032574A (ko) * 2002-10-03 2012-04-05 탈자진 인코포레이티드 혈관항상성 유지제 및 그의 사용 방법
ES2211344B1 (es) * 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
US20090048255A1 (en) * 2003-07-21 2009-02-19 Schumacher Richard A Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
MY141255A (en) * 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
NZ588139A (en) 2004-04-08 2012-02-24 Targegen Inc 7-Aryl-3-arylamino-benzo[1,2,4]triazine derivatives
ES2251866B1 (es) * 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) * 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
AU2005276974B2 (en) 2004-08-25 2012-08-02 Targegen, Inc. Heterocyclic compounds and methods of use
EP1888528A2 (fr) * 2005-06-10 2008-02-20 Memory Pharmaceuticals Corporation Inhibiteurs de la phosphodiesterase 4
US8389538B2 (en) * 2007-02-27 2013-03-05 National University Corporation Okayama University Rexinoid compound having alkoxy group
ES2320954B1 (es) * 2007-03-02 2010-03-16 Laboratorio Almirall S.A. Nuevo procedimiento de preparacion de 3-metil-4-fenilisoxazolo (3,4-d)iridazin-7(6h)-ona.
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
WO2008127975A2 (fr) * 2007-04-11 2008-10-23 Alcon Research, Ltd. Utilisation d'un inhibiteur de tnfa et d'une anti-histamine pour traiter la rhinite allergique et la conjonctivite allergique
WO2009067607A2 (fr) * 2007-11-20 2009-05-28 Memory Pharmaceuticals Corporation Combinaisons d'inhibiteurs de pde4 et d'antipsychotiques pour le traitement de troubles psychotiques
EP2070913A1 (fr) 2007-12-14 2009-06-17 CHIESI FARMACEUTICI S.p.A. Dérivés d'ester en tant qu'inhibiteurs de la phosphodiestérase
EP2110375A1 (fr) * 2008-04-14 2009-10-21 CHIESI FARMACEUTICI S.p.A. Inhibiteurs de la phosphodiestérase de type 4 appartenant à la classe tertiaire d'amine
US20100029689A1 (en) * 2008-07-02 2010-02-04 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
JP5542059B2 (ja) * 2008-10-09 2014-07-09 国立大学法人 岡山大学 Ｒｘｒ作動性物質を有効成分とする抗アレルギー剤
JP5721722B2 (ja) * 2009-10-01 2015-05-20 アルコン リサーチ， リミテッド オロパタジン組成物およびその使用
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
RU2668073C2 (ru) 2013-03-14 2018-09-26 Дарт Нейросайенс (Кайман) Лтд. Замещенные пиридиновые и пиразиновые соединения в качестве ингибиторов pde4

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698711A (en) 1991-01-28 1997-12-16 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
US5935978A (en) 1991-01-28 1999-08-10 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
GB9311281D0 (en) 1993-06-01 1993-07-21 Rhone Poulenc Rorer Ltd Novel composition of matter
US6096768A (en) 1992-01-28 2000-08-01 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
EP0607373B1 (fr) 1992-06-15 1997-03-19 Celltech Therapeutics Limited Derives a groupe phenyle trisubstitue utilises comme inhibiteurs selectifs de la phosphodiesterase iv
US5679696A (en) 1992-07-28 1997-10-21 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic-or heteroatom-containing linking group
PT652868E (pt) 1992-07-28 2005-01-31 Aventis Pharma Ltd Inibidores da fosfodiesterase do amp ciclico
US5814651A (en) 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
TW263495B (fr) 1992-12-23 1995-11-21 Celltech Ltd
US5622977A (en) 1992-12-23 1997-04-22 Celltech Therapeutics Limited Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same
RU2083562C1 (ru) * 1993-02-05 1997-07-10 Исихара Сангио Кайся Лтд. Производные пиридина, способ их получения, инсектицидная композиция
GB9304920D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304919D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
AU6971894A (en) 1993-05-27 1994-12-20 Smithkline Beecham Laboratoires Pharmaceutiques Anti-arrhythmic n-substituted 3-benzazepines or isoquinolines
SI0706513T1 (en) 1993-07-02 2002-10-31 Altana Pharma Ag Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors
GB9315595D0 (en) * 1993-07-28 1993-09-08 Res Inst Medicine Chem New compounds
WO1995017399A1 (fr) 1993-12-22 1995-06-29 Celltech Therapeutics Limited Derives de phenyle trisubstitues, leurs procedes de preparation et leur utilisation sous forme d'inhibiteurs de la phosphodiesterase (type iv)
GB9326699D0 (en) 1993-12-22 1994-03-02 Celltech Ltd Chemical compounds
GB9401460D0 (en) * 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
ES2293638T3 (es) 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US5786354A (en) 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
US6245774B1 (en) 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
GB9412571D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412573D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412672D0 (en) 1994-06-23 1994-08-10 Celltech Ltd Chemical compounds
US5591776A (en) 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
FR2729142A1 (fr) 1995-01-06 1996-07-12 Smithkline Beecham Lab Nouvelles amines heterocycliques, leur procede de preparation et leur utilisation en tant que medicaments et notamment en tant qu'agents anti-arythmiques
US5731477A (en) 1995-01-31 1998-03-24 Smithkline Beecham Corporation Method for synthesis of aryl difluoromethyl ethers
US5728712A (en) 1995-05-19 1998-03-17 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
IT1275433B (it) 1995-05-19 1997-08-07 Smithkline Beecham Farma Derivati di diarildiammine
FR2735777B1 (fr) 1995-06-21 1997-09-12 Sanofi Sa Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
US5710170A (en) 1995-12-15 1998-01-20 Merck Frosst Canada, Inc. Tri-aryl ethane derivatives as PDE IV inhibitors
WO1997022586A1 (fr) * 1995-12-15 1997-06-26 Merck Frosst Canada Inc. Derives d'ethane tri-aryle utilises comme inhibiteurs de pde iv
GB9603723D0 (en) 1996-02-22 1996-04-24 Merck & Co Inc Diphenyl pyridyl derivatives as pde iv inhibitors
GB9526243D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526245D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526246D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
JP4373497B2 (ja) * 1996-06-19 2009-11-25 ローン−プーラン・ロレ・リミテツド 置換されたアザビシクロ化合物、ならびにｔｎｆおよびサイクリックａｍｐホスホジエステラーゼ産生の阻害剤としてのそれらの使用
BR9712782A (pt) 1996-06-25 1999-12-07 Pfizer Derivados de indazol substituìdo e seu uso como inibidores de fosfodiesterose (pde) e fator de necrose de tumor (tnf)
JPH1072415A (ja) 1996-06-26 1998-03-17 Nikken Chem Co Ltd ３−アニリノ−２−シクロアルケノン誘導体
JP3554337B2 (ja) 1996-09-04 2004-08-18 ファイザー・インク インダゾール誘導体、およびホスホジエステラーゼ（ｐｄｅ）タイプ４と腫瘍壊死因子（ｔｎｆ）産生の阻害剤としてのインダゾール誘導体の使用
GB9622386D0 (en) 1996-10-28 1997-01-08 Sandoz Ltd Organic compounds
GB9625184D0 (en) 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds
US6235736B1 (en) * 1997-06-24 2001-05-22 Nikken Chemicals Co., Ltd. 3-anilino-2-cycloalkenone derivatives
TW374919B (en) * 1997-08-28 1999-11-21 Hitachi Ltd Synchronous memory unit
US5919937A (en) 1997-10-29 1999-07-06 Merck & Co., Inc. Process for phosphodiesterase IV inhibitors
WO1999026616A1 (fr) 1997-11-25 1999-06-03 Warner-Lambert Company Inhibiteurs benzenesulfamides de la phosphodiesterase iv et utilisation therapeutique de ces derniers
ES2251121T3 (es) 1997-12-24 2006-04-16 Ortho-Mcneil Pharmaceutical, Inc. (4)-aril(piperidin-4-il) aminobenzamidas que se unen al receptor opioide delta.
JP3542482B2 (ja) 1997-12-25 2004-07-14 日研化学株式会社 ３−アニリノ−２−シクロアルケノン誘導体
AU2529799A (en) * 1998-02-09 1999-08-23 Darwin Discovery Limited Benzofuran-4-carboxamides and their therapeutic use
JP2002537383A (ja) * 1999-02-25 2002-11-05 メルク フロスト カナダ アンド カンパニー Ｐｄｅｉｖ阻害化合物、組成物および治療方法
US6180650B1 (en) 1999-04-23 2001-01-30 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE 4 inhibitors
US6200993B1 (en) 1999-05-05 2001-03-13 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE4 inhibitors
GB2350110A (en) 1999-05-17 2000-11-22 Bayer Ag Pharmaceutically active benzofurans
DK1183033T3 (da) 1999-05-21 2006-06-06 Bristol Myers Squibb Co Pyrrolotriazininhibitorer af kinaser
JP4434362B2 (ja) 1999-06-28 2010-03-17 興和創薬株式会社 ホスホジエステラーゼ阻害剤
EP1116711B1 (fr) 1999-12-18 2005-12-14 Wella Aktiengesellschaft Dérivés de 2-aminoalkyl-1,4-diaminobenzène et composition tinctoriale les contenant
MY123585A (en) * 2000-03-23 2006-05-31 Merck Canada Inc Tri-aryl-substituted-ethane pde4 inhibitors.
JP2003534328A (ja) * 2000-05-25 2003-11-18 メルク フロスト カナダ アンド カンパニー フルオロアルコキシ置換ベンズアミドジクロロピリジニルｎ−オキシドｐｄｅ４阻害剤
ES2556946T3 (es) 2000-12-21 2016-01-21 Novartis Ag Pirimidinaminas como moduladores de la angiogénesis
US6699890B2 (en) 2000-12-22 2004-03-02 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
CZ20031986A3 (cs) * 2001-01-22 2003-12-17 Memory Pharmaceuticals Corporation N-substituované aniliny a difenylaminy inhibující PDE4 a farmaceutický prostředek, který je obsahuje
EP1539697A1 (fr) * 2002-07-19 2005-06-15 Memory Pharmaceutical Corporation Inhibiteurs de phosphodiesterase 4 comprenant des analogues de diphenylamine et d'aniline n-substitues

Also Published As

Publication number Publication date
JP2006508987A (ja) 2006-03-16
ZA200503995B (en) 2006-08-30
NZ540138A (en) 2008-07-31
US7087625B2 (en) 2006-08-08
KR20050075430A (ko) 2005-07-20
WO2004046113A3 (fr) 2005-03-24
MXPA05005345A (es) 2005-08-26
RU2356893C2 (ru) 2009-05-27
NO20052976D0 (no) 2005-06-17
WO2004046113A2 (fr) 2004-06-03
DE60334243D1 (de) 2010-10-28
EP1569908A2 (fr) 2005-09-07
EP1569908B1 (fr) 2010-09-15
BR0315705A (pt) 2005-09-06
US7700631B2 (en) 2010-04-20
RU2005119627A (ru) 2006-01-27
CA2506297A1 (fr) 2004-06-03
AU2003295656A1 (en) 2004-06-15
CN100513397C (zh) 2009-07-15
US20060211865A1 (en) 2006-09-21
ATE481387T1 (de) 2010-10-15
AU2003295656B2 (en) 2010-11-11
US20100173942A1 (en) 2010-07-08
CN1714081A (zh) 2005-12-28
AU2003295656A2 (en) 2005-06-30
US20040152902A1 (en) 2004-08-05

Similar Documents

Publication Publication Date Title
NO20052976D0 (no) Fosfodiesterase-4-inhibitorer.
TW200602322A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
YU57603A (sh) Inhibitori fosfodiesteraze 4
ATE449099T1 (de) Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren
NO20070606L (no) Inhibitorer av IAP
TNSN03045A1 (fr) Quinazolines as mmp-13 inhibitors
ES2193839B1 (es) Nuevos derivados de 6-fenildihidropirrolpirimidindiona.
ATE338461T1 (de) Pyrazolpyrimidinfungizide
ATE389638T1 (de) Aminobenzamidderivate als inhibitoren der glycogensynthasekinase-3-
DE602005010413D1 (de) Phosphonatanaloga von hiv-integrasehemmerverbindungen
CY1106132T1 (el) Παραγωγα πιπepιδινης ως αναστολεις καναλιου καλιου
CO5570674A2 (es) Derivados de 4-(4-alcoxi-3-hidroxifenil)-2-pirrolidona como inhibidores de pde-4 para el tratamiento de sindromes neurologicos
WO2010003084A3 (fr) Inhibiteurs de la phosphodiestérase 4
AR042362A1 (es) Derivados de 3h-quinazolin-4-ona, proceso de obtencion y composiciones farmaceuticas que los contienen
DE60314381D1 (de) Benzylimidazolyl substituierte 2-chinolon und chinazolinon derivate zur verwendung als farnesyl transferase inhibitoren
DE60325984D1 (de) 4-aminobenzofuranverbindungen als phosphodiesterase-4-inhibitoren
HRP20090264T1 (hr) Derivati fenil-piperazin metanona
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
EA200800070A1 (ru) Производные 2-(1h-индолилсульфанил)ариламина
TNSN05277A1 (en) Novel bioisosteres of actinonin
NO20064491L (no) Nye difluomtoksysubstituee hydroksy-6-fenylfenantridiner og deres anvendelse som PDE4-inhibitorer
ATE399169T1 (de) Imidazopyridinderivate als inhibitoren der induzierbaren no-synthase
NO20062152L (no) Fremstilling av 3-azabicyklo [3.1.0.]heksanderivater
ATE374751T1 (de) 3,4-dihydro-1h-chinolin-2-onderivate als norepinephrin-wiederaufnahme-hemmern
NO20050764L (no) Forbindelser